RxDoctor Payments DataLook up a doctor →

Ravi Shah, MD

Neurology · Parker, CONPI 1013999895

Payments from drug & device makers

$1,298,570in general payments, 2019–2025

Across 2,853 payments — averaging $455.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$961K
  • Amgen$93K
  • Biohaven Pharmaceuticals, Inc.$73K
  • Pfizer$39K
  • Axsome Therapeutics, Inc.$34K
  • Impel Pharmaceuticals Inc.$32K
  • plus $67K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)1,267$960,601
Amgen(2 entities)184$92,758
Biohaven Pharmaceuticals, Inc.128$72,725
Pfizer115$38,538
Axsome Therapeutics, Inc.57$33,701
Impel Pharmaceuticals Inc.41$32,442
Teva Pharmaceuticals USA, Inc.84$17,421
Biohaven Pharmaceutical Holding Company Ltd.49$16,274
Lundbeck LLC75$13,180
Novartis68$4,199
Promius Pharma LLC10$1,474
Neurocrine Biosciences, Inc.103$1,251
UCB, Inc.35$963
Biogen52$916
Avanir Pharmaceuticals, Inc.8$880
AstraZeneca(2 entities)36$810
Lilly USA, LLC41$650
Bristol Myers Squibb24$620
SK Life Science, Inc.23$563
Argenx US, Inc.20$532
Tanabe Pharma America, Inc.24$488
Sanofi23$450
Supernus Pharmaceuticals, Inc.32$439
Neurelis, Inc.15$357
MDD US Operations, LLC20$351
Jazz Pharmaceuticals Inc.7$298
Livanova USA, Inc.17$286
Acadia Pharmaceuticals Inc16$282
Akcea Therapeutics, Inc.18$268
Boston Scientific6$266
Abbott9$248
Eisai Inc.12$238
Johnson & Johnson(2 entities)11$235
CSL Behring10$203
Scilex Pharmaceuticals Inc.15$196
Grifols USA, LLC10$192
EMD Serono, Inc.11$192
Zyla Life Sciences, Inc.30$181
Mallinckrodt Hospital Products Inc.10$161
Alnylam Pharmaceuticals Inc.6$156
Tonix Medicines, Inc.1$148
Merz Pharmaceuticals, LLC7$147
Sunovion Pharmaceuticals Inc.10$131
Catalyst Pharmaceuticals, Inc.7$128
Greenwich Biosciences, Inc.5$127
Upsher-smith Laboratories LLC9$126
Ipsen Biopharmaceuticals, Inc4$126
Vanda Pharmaceuticals Inc.5$123
Takeda Pharmaceuticals U.S.A., Inc.6$112
Otsuka America Pharmaceutical, Inc.4$91
Medtronic(2 entities)5$88
Kyowa Kirin, Inc.4$81
E.r. Squibb & Sons, L.L.C.5$79
Amylyx Pharmaceuticals, Inc.3$75
Merz North America, Inc.4$72
Mallinckrodt Enterprises LLC5$70
Assertio Therapeutics, Inc.4$62
Acorda Therapeutics, Inc3$57
Aquestive Therapeutics, Inc.3$54
GRT US Holding, Inc.4$53

How this compares

$1,298,570 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado →

Medicare billing

Part B allowed, 2024
$583,425
Medicare patients
327
Services billed
70,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Parker

See the full list for Colorado →

Where these figures come from

Is this you, or does something look wrong? →